Pulmatrix and Eos SENOLYTIX to Merge Advancing Mitochondrial Therapies

Pulmatrix Inc. and Eos SENOLYTIX have agreed to merge, a move intended to speed up the advancement of new therapies focused on mitochondrial function. The combined entity aims to improve human healthspan by developing treatments that address cellular energy production.

The merger will see the new company concentrate on therapies designed to normalize mitochondrial function. Mitochondria, responsible for a cell's energy, are critical in the aging process and the development of various diseases. The joint venture is expected to leverage the expertise and technology of both founding companies to achieve its goals.

Pulmatrix has previously focused on respiratory disease treatments, while Eos SENOLYTIX has explored senolytics—compounds that clear out senescent cells—for age-related conditions. The companies believe this consolidation will broaden the scope of potential applications and expedite clinical progress.

Specific terms of the merger have not been disclosed. However, the union is anticipated to bolster the companies' standing in the health and longevity research sector. Details regarding the new company's leadership and strategic direction will be announced in due course.